| Home > Articles > Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: A phase 1 clinical trial > Access to Fulltext |
|
|
|||||||
| version 1 |
| ||||||